drugset / Trial / NCT00143273

Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation

NCT00143273

Phase 2 Completed 497 enrolled Ligand Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women.

Timeline

Start
2004-06
Primary completion
2006-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lasofoxifene Small molecule 0.05 mg
Subject Lasofoxifene Small molecule 0.25 mg
Subject Lasofoxifene Small molecule 0.5 mg

Indications